Sona Nano Ends COVID Trials

Sona Nanotech shares fell 68 percent on Friday after the Halifax life sciences company announced it had ended the clinical trials of its saliva-based rapid test for COVID-19 due to disappointing results.
The company had been conducting trials at Humber River Hospital in Toronto to determine the efficacy of its rapid antigen saliva test for COVID-19. Early Friday, Sona said preliminary results